| atezolizumab vs docetaxel | No demonstrated result suggested death (overall survival) by 27% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | 0.73 [0.63 0.84] | p=0.04 | 0 | 1512 | 2 | POPLAR Phase 2 atezolizumab,OAK, | | progression or death (progression free survival PFS) | 0.95 [0.82 1.10] | p=1.00 | 0 | 1225 | 1 | OAK, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab + bevacizumab vs bevacizumab (on top platinum-based CT) | No demonstrated result suggested progression or death (progression free survival PFS) by 41% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 1.01 [0.31 3.22] | p=1.00 | 0 | 976 | 2 | IMpower150 (WT),IMpower150 (Teff), | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.59 [0.51 0.68] | p=0.04 | 0 | 1492 | 2 | IMpower150 (WT),IMpower150 (Teff), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab + platinum-based CT vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab vs chemotherapy | No demonstrated result suggested Grade 3–5 drug-related AEs by 54% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 1.07 [0.57 1.99] | p=1.00 | 0 | 229 | 1 | IMvigor211 (IC2/3), | | complete response (CR) | no data | | death (overall survival) | 0.87 [0.63 1.21] | p=1.00 | 0 | 234 | 1 | IMvigor211 (IC2/3), | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | 0.46 [0.35 0.63] | p=0.04 | 0 | 902 | 1 | IMvigor211 (IC2/3), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab vs nil | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| atezolizumab + CT vs chemotherapy | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
